REFERENCES
- Davies DE, Chamberlin SG. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996; 51: 1101–10.
- Needle MN. Safety experience with IMC-C225, an anti-epider-mal growth factor receptor antibody. Semin Oncol 2002; 29(Suppl 14): 55–60.
- Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichome-galy. Acta Oncol 2003; 42(4): 345–6.
- Salt L, Abbruzzese JL, Arzania M, Needle M. The presence and intensity of the cetuximab-induced acne-like rash increased survival in studies across multiple malignacies. J Clin Oncol, Proceedings of ASCO annual meeting 2003, Abstract 871.
- King LE Jr, Gates RE, Stoscheck CM, Nanney LB. The EGF/TGF alpha receptor in skin. J Invest Dermatol 1990; 94\(Suppl 6): 164S–70S.
- Van Ruissen F, de Jongh GJ, van Erp PE, Boezeman JB, Schalkwijk J. Cell kinetic characterization of cultured human keratinocytes from normal and psoriatic individuals. J Cell Physiol 1996; 168: 684–94.
- King LE Jr, Gates RE, Stoscheck CM, Nanney LB. Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. J Invest Dermatol 1990; 95: 10S–2S.
- Ben-Bassat H, Klein BY Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 2000; 6: 933–42.